Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Charles P. Vega, MD
Let’s Examine Collaborative Patient Management in ASCVD Risk Reduction
Mark J. Alberts, MD
Matthew Jay Budoff, MD
Lawrence A. Leiter, MD
Omega-3 Icosapent Ethyl and Stroke Reduction in Atherosclerotic Vascular Disease
Javed Butler, MD, MBA, MPH
Shelley Zieroth, MD
High-Risk HFrEF: Who Will Benefit Most from Novel Therapies?
Peter Libby, MD
Prof. Kausik Ray, MBChB, MD, MPhil
Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction
Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASC…
Joseph Saseen, PharmD, BCPS, BCACP, CLS
Variable Effects of Omega-3 Fatty Acids for ASCVD Event Reduction: Why?